Pfizer to pay $784.6 million fine due to Wyeth Medicaid fraud
April 28, 2016Medical Communications, Sales and Marketing False Claims Act, Medicaid, Pfizer, US, Wyeth, department, fraud, insurer, justice
Pfizer has agreed to pay $784.6 million in a settlement with the US Department of Justice, relating to false and …
Sanofi makes unsolicited $9.8 billion bid for Medivation
April 28, 2016Research and Development, Sales and Marketing M&A, MA, Medivation, Sanofi, deal, unsolicited offer
French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 …
SHL at the 2016 Prefillied Syringes Seminar Tokyo
April 28, 2016Manufacturing and Production
SHL is glad to announce that it is going to participate in the Prefilled Syringe Seminar 2016 Tokyo, organized by …
GlaxoSmithKline Q1 earnings up 14% on new product sales
April 27, 2016Research and Development, Sales and Marketing GSK, GlaxoSmithKline, Q1, earnings, results, revenue, sales
GlaxoSmithKline (LSE: GSK) reported a 14% rise in first-quarter earnings driven by demand for new drugs. The UK drug firm …
New head of R&D at Biogen
April 27, 2016Research and Development Biogen, Pfizer, R&D, erhlers, michael, michael erhlers, research and development
Biogen (NASDAQ: BIIB) has announced the appointment of Dr Michael Ehlers as executive vice president, research and development. His role …
NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis
April 27, 2016Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation
The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …
NICE gives green light to Novartis’s heart drug Entresto
April 27, 2016Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients
NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …
Remaining in the EU is vital for UK’s cancer research strength, say leading oncologists
April 27, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, EU, Europe, UK, brexit, britain, cancer research, cede, exit, implications, negative, oncology, pharma
Leading UK oncologists have written an article in the May issue of The Lancet, strongly urging Britain to remain in …
Baxter hikes 2016 earnings view driven by strong Q1 results
April 27, 2016Research and Development, Sales and Marketing Baxalta, FY, Q1, baxter, earnings, outlook, results, revenue
Baxter International (NYSE: BAX) reported better-than-expected first-quarter profits and raised its earnings outlook for 2016. The company now sees earnings …
Eli Lilly Q1 earnings miss estimates, ups FY view; shares drop 2%
April 27, 2016Research and Development, Sales and Marketing Eli Lilly, FY, Q1, earnings, revenue, sales
Shares in US drugmaker Eli Lilly (NYSE: LLY) dropped to close down over 2% Tuesday after the company posted first-quarter …
ABPI welcomes recommendations from NHS specialised services report
April 27, 2016Research and Development, Sales and Marketing ABPI, NHS, NHS England, NICE, National Audit Office, report, specialised services
The ABPI has welcomed the findings of a National Audit Office report on the commission of specialised service by NHS …
Shire to close Hampshire base and relocate jobs, say reports
April 27, 2016Manufacturing and Production, Research and Development Jobs, Shire, close, factory, hampshire, loss, relocate
Shire is set to cease operations at its site in Basingstoke, Hampshire, by the end of next year and relocate …
AstraZeneca sells US rights for gout treatment to Ironwood Pharmaceuticals
April 27, 2016Research and Development, Sales and Marketing AstraZeneca, Ironwood, Licencing, Zurampic, agreement, exclusive, gout, lesinurad, sales
AstraZeneca (LSE: AZN) has entered into a licencing agreement with Ironwood Pharmaceuticals (NASDAQ: IRWD) which will see the latter granted …
Novartis’ Ilaris gets US FDA breakthrough therapy designation to treat fever syndromes
April 27, 2016Business Services, Research and Development Breakthrough Therapy Designation, Novartis, US FDA, periodic fever syndromes
Novartis (VTX: NOVN) on Wednesday said its drug to treat three rare types of periodic fever syndromes has been granted …
Eli Lilly gets European marketing authorisation for psoriasis drug
April 26, 2016EC, EU, Eli Lilly, drug trial, psoriasis, regulation
US pharma firm Eli Lilly and Co (NYSE: LLY) on Tuesday said the European Commission backed marketing authorisation for its …
Eisai poaches senior Pfizer and Sanofi execs for neurology group
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim
Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …
Perrigo name new head of its combined UK and Ireland business
April 26, 2016Sales and Marketing Ireland, Perrigo, UK, lister, neil, new head
Perrigo has named Neil Lister as the head of its newly-combined UK and Ireland business. The manufacturer and distributor of …
Northern Powerhouse life sciences contributing £10 billion to UK economy, says minister
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Jobs, Northern Powerhouse, contribution, economy, exporting, george freeman, investment, life sciences, minister, north
Minister for Life Sciences, George Freeman MP, has revealed that life sciences businesses within the Northern Powerhouse are contributing over …
US panel says Sarepta’s trial DMD drug not proven effective
April 26, 2016Manufacturing and Production, Research and Development DMD, US FDA, drug trial, sarepta
A US advisory committee has concluded Sarepta Therapeutics’ (Nasdaq: SRPT) trial drug to treat muscle wasting condition has not proved …
Bayer’s earnings beat estimates as blockbusters shine
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales
Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
